文献速递血栓与止血

血小板生成素受体激动剂治疗可补充免疫性血小板减少症患者脾脏微环境中的调节性T细胞

Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists.
PubMed 文献 · Br J Haematol · 2022-06-24

免疫性血小板减少症(ITP)的治疗仍具挑战性,血小板生成素受体激动剂(TPO-RA)已革新ITP治疗格局。Pizzi等的研究表明,TPO-RA治疗可恢复ITP患者脾脏微环境中降低的调节性T细胞(Treg)数量,支持TPO-RA可能具有免疫调节作用的假说。

要点

  • TPO-RA治疗可恢复ITP患者脾脏微环境中降低的Treg数量。
  • 研究支持TPO-RA在ITP中可能具有免疫调节作用的假说。
  • TPO-RA已革新ITP治疗格局,但ITP治疗管理仍具挑战性。

核心结论

  • TPO-RA治疗可恢复ITP患者脾脏微环境中降低的Treg数量,支持TPO-RA可能具有免疫调节作用的假说。

研究设计与样本

  • 本文为针对Pizzi等研究(Br J Haematol. 2022;198:916-922)的评论文章。

主要发现

  • TPO-RA治疗使ITP患者脾脏微环境中降低的Treg数量得到恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO-RAs) have revolutionised the treatment landscape of ITP. It is increasingly hypothesised that TPO-RAs may have an immune modulatory role and Pizzi and colleagues provide evidence in support of this by demonstrating that TPO-RA treatment restores the decreased regulatory T cell (Treg) numbers in the splenic microenvironment of patients with ITP. Commentary on: Pizzi M, Vianello F, Binotto G, Vianelli N, Carli G, Auteri G, et al. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in Immune Thrombocytopenia. Br J Haematol. 2022;198:916-922.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kapur R. Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists. Br J Haematol. 2022. PMID: 35748239. doi:10.1111/bjh.18332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。